Fox Run Management’s Capricor Therapeutics CAPR Stock Holding History

Fox Run Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,360	Closed	-$212K	–	894
2025 Q1	$212K	Buy	+22,360	New	+$310K	0.03%	783

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

BDF

Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fox Run Management's CAPR Position: Q2 2025 in Review

Fox Run Management sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 22,360 shares — an estimated $212K sold.

Fox Run Management first reported a position in CAPR in Q1 2025 and held it in 1 quarter. The position peaked at $212K in Q1 2025. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

Fox Run Management reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 22,360 Capricor Therapeutics shares in Q2 2025, an estimated $212K.
Fox Run Management first reported a position in Capricor Therapeutics in Q1 2025 and held it in 1 quarter.
Fox Run Management's Capricor Therapeutics position peaked at $212K in Q1 2025.
107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.